GlaxoSmithKline plc (NYSE:GSK) saw some unusual options trading on Tuesday. Stock traders acquired 32,352 put options on the stock. This is an increase of approximately 2,217% compared to the typical daily volume of 1,396 put options.
A number of institutional investors and hedge funds have recently made changes to their positions in GSK. FinTrust Investment Advisory Services LLC acquired a new position in shares of GlaxoSmithKline in the 3rd quarter valued at about $401,000. Private Advisor Group LLC lifted its stake in shares of GlaxoSmithKline by 7.2% in the 3rd quarter. Private Advisor Group LLC now owns 77,976 shares of the pharmaceutical company’s stock valued at $3,166,000 after purchasing an additional 5,212 shares during the period. San Francisco Sentry Investment Group CA lifted its stake in shares of GlaxoSmithKline by 110.3% in the 3rd quarter. San Francisco Sentry Investment Group CA now owns 8,749 shares of the pharmaceutical company’s stock valued at $356,000 after purchasing an additional 4,589 shares during the period. SG Americas Securities LLC acquired a new position in shares of GlaxoSmithKline in the 3rd quarter valued at about $1,209,000. Finally, Fulton Bank N.A. lifted its stake in shares of GlaxoSmithKline by 4.9% in the 3rd quarter. Fulton Bank N.A. now owns 75,269 shares of the pharmaceutical company’s stock valued at $3,056,000 after purchasing an additional 3,515 shares during the period. 9.66% of the stock is currently owned by hedge funds and other institutional investors.
GlaxoSmithKline (GSK) opened at $36.17 on Friday. The company has a market capitalization of $89,230.00, a PE ratio of 42.06, a price-to-earnings-growth ratio of 2.31 and a beta of 0.98. GlaxoSmithKline has a twelve month low of $34.52 and a twelve month high of $44.53. The company has a current ratio of 0.64, a quick ratio of 0.44 and a debt-to-equity ratio of 2.96.
Several research firms recently weighed in on GSK. UBS Group raised GlaxoSmithKline from a “neutral” rating to a “buy” rating and raised their price objective for the company from $35.04 to $35.85 in a report on Monday, November 27th. JPMorgan Chase & Co. reissued a “neutral” rating on shares of GlaxoSmithKline in a report on Monday, January 29th. Cowen set a $38.00 price objective on GlaxoSmithKline and gave the company a “hold” rating in a report on Monday, December 11th. ValuEngine downgraded GlaxoSmithKline from a “buy” rating to a “hold” rating in a report on Sunday, December 31st. Finally, Barclays raised GlaxoSmithKline from an “equal weight” rating to an “overweight” rating in a report on Tuesday, January 16th. Three investment analysts have rated the stock with a sell rating, ten have issued a hold rating and six have given a buy rating to the company’s stock. GlaxoSmithKline currently has an average rating of “Hold” and a consensus target price of $38.57.
COPYRIGHT VIOLATION WARNING: This news story was originally reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of US and international trademark and copyright law. The legal version of this news story can be accessed at https://sportsperspectives.com/2018/02/09/glaxosmithkline-sees-unusually-high-options-volume-gsk.html.
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.